Pavnell

Pavnell is a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company utilizes a proprietary drug discovery platform to identify highly selective modulators for historically challenging GPCR targets involved in pain, inflammation, and metabolic diseases. By leveraging structural biology and advanced screening techniques, Pavnell aims to create next-generation treatments with improved efficacy and reduced side-effect profiles. The company's current pipeline is in the pre-clinical stage, focusing on validating lead candidates for transition into clinical trials.